Over 85 warning letters have been issued in two enforcement waves, primarily targeting two kinds of marketing claims: implying compounded products are equivalent to FDA-approved drugs, and misrepresenting which entity is doing the actual compounding
Theres no question cataracts are related to lead
These forms are not the same as the approved drug that uses semaglutide base as the active ingredient
For context, NICE has issued technology appraisals for semaglutide (Wegovy) for weight management and for tirzepatide (Mounjaro) for weight management, each with specific eligibility criteria based on BMI and the presence of weight-related comorbidities
Buyer Takeaway: The foundational legitimacy indicators - LegitScript, publicly accessible legal documentation, an established and independently verified medical group - are present and verifiable
*Correspondence: Salvatore Corrao, [email protected]